Skip to main content
. 2018 Oct 17;2018:8012747. doi: 10.1155/2018/8012747

Table 2.

Proportion of polymorphisms according to time in therapeutic range.

Total cohort (n=212) TTR <70% (n=128, 60.4%) TTR ≥70% (n=84, 39.6%) p-value
VKORC ≥ 1 allele T, (TT/CT), n (%) 138 (65.1) 85 (66.4) 53 (63.1) 0.621
CYP2C9 2 ≥1 allele T (TT/CT), n (%) 75 (35.4) 44 (34.4) 31 (36.9) 0.706
CYP2C9 3 ≥ 1 allele C (CC/CA), n (%) 35 (16.5) 20 (15.6) 15 (17.9) 0.669
MIR133A2 ≥ 1 allele A (AA/GG), n (%) 82 (38.7) 51 (39.8) 31 (36.9) 0.667

TTR, time in therapeutic range.